Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first‐line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher‐risk populations with relapsed/refractory (R/R) disease. The objective of thi...

Full description

Saved in:
Bibliographic Details
Published in:Am J Hematol
Main Authors: O'Brien, Susan M., Byrd, John C., Hillmen, Peter, Coutre, Steven, Brown, Jennifer R., Barr, Paul M., Barrientos, Jacqueline C., Devereux, Stephen, Robak, Tadeusz, Reddy, Nishitha M., Kipps, Thomas J., Tedeschi, Alessandra, Cymbalista, Florence, Ghia, Paolo, Chang, Stephen, Ninomoto, Joi, James, Danelle F., Burger, Jan A.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593416/
https://ncbi.nlm.nih.gov/pubmed/30767298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25436
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items